Vibrenta SC Injection contains Insulin Glargine (rDNA)
Vibrenta SC Injection uses for
Insulin Glargine is indicated for once-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.
The recommended starting dose of Insulin Glargine in patients with type 1 diabetes should be approximately one-third of the total daily insulin requirements. Short-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements.
The recommended starting dose of Insulin Glargine in patients with type 2 diabetes who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted to the patient’s needs.
The dose of Insulin Glargine should be adjusted according to blood glucose measurements. The dosage of Insulin Glargine should be individualized under the supervision of a healthcare provider in accordance with the needs of the patient.
Do not dilute or mix with any other insulin or solution. Do not administer subcutaneously via an Insuliln pump or intravenously because severe hypoglycemia can occur. Do not share reusable or disposable insulin glargine devices or needles between patients.
Insulin glargine overdose may result in hypoglycemia. Mild episodes of hypoglycemia can usually be treated with oral carbohydrates. Severe hypoglycemia may be treated with parenteral glucose or injections of glucagon. Adjustments in drug dosage, meal patterns, or exercise may be needed.
Read more here Vibrenta